CKD BURDEN

THE IMPACT OF CHRONIC KIDNEY DISEASE ON PATIENTS WITH TYPE 2 DIABETES IS FAR-REACHING

As of 2019, approximately 463 million adults ages 20–79 have diabetes worldwide, of which around 90% have T2D¹

Up to 40% of patients with type 2 diabetes develop chronic kidney disease²

Patients with stage 3 CKD are 10x more likely to die from any cause (including CV disease) than to progress to stage 5 CKD, dialysis, or kidney transplantation³*

CKD can shorten life expectancy of patients with diabetes by up to 16 years, relative to the general population with neither disease⁴

*A Norwegian 10-year observational study of patients with CKD stage 3 (N=3047).³

Risk of CV events appears early in the course of CKD in patients with T2D and grows with disease severity.⁵

COMPARED WITH T2D ALONE, COMORBID KIDNEY DISEASE INCREASES CV MORTALITY⁶

CKD and T2D increase 10-year CV mortality chart

CKD PROGRESSION CAN HAVE SERIOUS CONSEQUENCES FOR PATIENTS

CKD progression in T2D follows a path toward declining kidney function, CV decline, and ultimately end-stage renal disease. Once renal function declines below a certain threshold, patients face the complications and risks associated with ESRD.^7,8

Despite the standard treatments for ESRD (transplant or dialysis), once patients reach ESRD, approximately 60% will die in the next 5 years. Organ shortages might result in limited transplantation. Even in the best-case scenario, dialysis care or transplantation will result in much less than a naturally functioning kidney, which is why protecting the kidney from CKD progression is of primary importance.^7,9,10

Current standard of care leaves patients open to the risks of inflammation and fibrosis, a largely unaddressed driver of CKD progression^2,11-16

Read on

CKD: chronic kidney disease; CV: cardiovascular; ESRD: end-stage renal disease; T2D: type 2 diabetes.

References:

International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels; 2019. Accessed January 12, 2021. Available at: https://www.diabetesatlas.org. Return to content
Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
Eriksen BO, et al. Kidney Int. 2006;69(2):375–382. Return to content
Wen CP, et al. Kidney Int. 2017;92(2):388–396. Return to content
Amod A, et al; DEVOTE Study Group. Diabetes Ther. 2020;11(1):53–70. Return to content
Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302–308. Return to content
Thomas MC, et al. Nat Rev Dis Primers. 2015;1. doi:10.1038/nrdp.2015.18. Return to content
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1–150. Return to content
Breyer MD, et al. Nat Rev Drug Discov. 2016;15(8):568–588. doi:10.1038/nrd.2016.67. Return to content
Pálsson R, et al. Adv Chronic Kidney Dis. 2014;21(3):273–280. Return to content
Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010. Return to content
Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
Black LM, et al. J Histochem Cytochem. 2019;67(9):663–681. Return to content
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content